Sopharma AD (FRA:3JR)

Germany · Delayed Price · Currency is EUR

3.250

+0.370 (12.85%)

Last updated: Oct 23, 2026, 9:43 PM CEST

Market Cap	1.79B +149.7%
Revenue (ttm)	1.45B +17.4%
Net Income	85.04M +64.9%
EPS	0.23 +121.8%
Shares Out	n/a
PE Ratio	14.28
Forward PE	n/a
Dividend	0.10 (2.99%)
Ex-Dividend Date	Jul 9, 2026

Volume	30
Open	3.000
Previous Close	2.880
Day's Range	3.000 - 3.250
52-Week Range	1.500 - 3.250
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; ... [Read more]

Industry Pharmaceutical Preparations

Founded 1933

Employees 6,049

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 3JR

Financial Performance

In 2025, Sopharma AD's revenue was 1.35 billion, an increase of 22.31% compared to the previous year's 1.10 billion. Earnings were 68.30 million, an increase of 74.61%.

Financial Statements